Cytovation welcomes new CEO

BERGEN, NORWAY, 1 September 2014 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disease, announces the appointment Kjell Inge Arnevig as its Chief Executive Officer. Kjell-Inge Arnevig has more than 25 years’ experience in senior and executive positions. Hi background is in transport and logistic and wholesale. From 1997-2002 Mr. Arnevig was CEO of an international fish farming equipment business with operations across two continents. Prior to this he was a private investor for 5 years. He was also general manager for an international Oil & Gas process equipment provider with special focus on Europe and the Middle-East and spent the last three years as Managing Director and CEO in Biotech and health related business. He studied Finance) at University of Bergen, and has a Bachelor’s degree from the Norwegian School of Management.

CEO of Cytovation, Kjell Inge Arnevig, said: “I am pleased to be joining Cytovation at this exciting time for the company. I am looking forward to supporting the development of Cytovation going forward, and I relish the opportunity to shape and drive the company’s vision and growth.”

Menu